Current status of lymph node-positive prostate cancer - Incidence and predictors of outcome

被引:52
作者
Swanson, Gregory P.
Thompson, Ian M.
Basler, Joseph
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Radiat Oncol, San Antonio, TX 78229 USA
[2] Univ Texas, Ctr Hlth Sci, Dept Urol, San Antonio, TX 78285 USA
关键词
DNA content; hormone-deprivation therapy; lymph node status; prostate-specific antigen; prostatectomy;
D O I
10.1002/cncr.22034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In early surgical series, the incidence of positive lymph nodes in patients with prostate cancer was approximately 40%. In the modern era of screening and improved patient selection, the incidence is now < 10%, although most series excluded patients with higher risk disease. The risk of having positive lymph nodes is influenced by disease stage, prostate-specific antigen level, and tumor grade and by the aggressiveness of lymph node dissection. Many of the same factors predict the outcome of these patients. Although the percentage of patients with positive lymph nodes has declined, there remain significant numbers of patients with lymph node-positive prostate cancer, and it remains a therapeutic dilemma.
引用
收藏
页码:439 / 450
页数:12
相关论文
共 112 条
[1]   PROGNOSTIC-SIGNIFICANCE OF EXTENT OF NODAL INVOLVEMENT IN STAGE-D1 PROSTATE-CANCER TREATED WITH RADIOTHERAPY [J].
ANSCHER, MS ;
PROSNITZ, LR .
UROLOGY, 1992, 39 (01) :39-43
[2]   LYMPH NODE METASTASES IN EARLY CARCINOMA OF PROSTATE [J].
ARDUINO, LJ ;
GLUCKSMAN, MA .
JOURNAL OF UROLOGY, 1962, 88 (01) :91-&
[3]  
Babayan R K, 1980, Prostate, V1, P345, DOI 10.1002/pros.2990010309
[4]   Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? [J].
Bader, P ;
Burkhard, FC ;
Markwalder, R ;
Studer, UE .
JOURNAL OF UROLOGY, 2003, 169 (03) :849-854
[5]  
BAGSHAW MA, 1984, UROL CLIN N AM, V11, P297
[6]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[7]   PROSTATIC ADENOCARCINOMA - RELATIONSHIP OF GRADE AND LOCAL EXTENT TO PATTERN OF METASTASES [J].
BARZELL, W ;
BEAN, MA ;
HILARIS, BS ;
WHITMORE, WF .
JOURNAL OF UROLOGY, 1977, 118 (02) :278-282
[8]   RADIATION-THERAPY IN ADENOCARCINOMA OF THE PROSTATE WITH PELVIC LYMPH-NODE INVOLVEMENT ON LYMPHADENECTOMY [J].
BATATA, MA ;
HILARIS, BS ;
CHU, FCH ;
WHITMORE, WF ;
SONG, HS ;
KIM, Y ;
HOROWITZ, B ;
SONG, KS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 (02) :149-153
[9]   No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in lowrisk patients with localized prostate cancer [J].
Bhatta-Dhar, N ;
Reuther, AM ;
Zippe, C ;
Klein, EA .
UROLOGY, 2004, 63 (03) :528-531
[10]   Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT [J].
Borley, NC ;
Fabrin, K ;
Sriprasad, S ;
Mondaini, N ;
Thompson, PM ;
Muir, GH ;
Poulsen, J .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2003, 37 (05) :382-386